Articles
19 September 2025
Vol. 3 No. 3 (2025)
Demographic and regional trends of heart failure and cachexia-related mortality among older adults in the United States, from 1999 to 2020
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
45
Views
45
Downloads
8
HTML
Authors
Cachexia is a debilitating yet under-recognized condition, particularly among the elderly population. It has been shown that patients with heart failure (HF) often have cachexia, leading to worsening mortality rates. There is limited research on mortality trends and demographic disparities in terms of cachexia. CDC WONDER (Centers for Disease Control and Prevention Wide-Ranging ONline Data for Epidemiologic Research) database was used, where HF and cachexia were listed as either contributory or underlying causes of death in adults >65 years from 1999-2020. Age-adjusted mortality rates (AAMRs) and annual percent changes (APC) were calculated and stratified by year, sex, race/ethnicity, and region. No change in mortality was seen due to HF + cachexia from 2004-2020 (APC -2.1%; 95% CI, -3.2 to 0.6). Almost half of the deaths (47%) occurred within nursing homes. Notably, White adults had a higher mortality than Black/ African American adults (23.8; 95% CI, 23.4 to 24.1 vs 18.4; 95% CI, 17.4 to 19.4). Mortality rates were also higher in rural areas than urban areas (27.9; 95% CI, 27.1 to 28.7 vs 22.1; 95% CI, 21.8 to 22.4). States in the top 90th percentile, including Idaho, Utah, Vermont, South Carolina, Alaska and New Hampshire, had 5-fold higher mortality than states in the lower 10th percentile. No change in mortality was seen due to HF and cachexia-related mortality in the last decade, with substantial racial and regional disparities. Targeted interventions are needed to curb these mortality trends.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Doehner W, Anker SD. Cardiac cachexia in early literature: a review of research prior to Medline. Int J Cardiol 2002;85:7-14. DOI: https://doi.org/10.1016/S0167-5273(02)00230-9
2. Bielecka-Dabrowa A, Ebner N, Dos Santos MR, et al. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail 2020;22:2314-26. DOI: https://doi.org/10.1002/ejhf.2011
3. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3. Erratum in: Lancet 1997;349:1258. DOI: https://doi.org/10.1016/S0140-6736(96)07015-8
4. Valentova M, Anker SD, von Haehling S. Cardiac cachexia revisited: the role of wasting in heart failure. Heart Fail Clin 2020;16:61-9. DOI: https://doi.org/10.1016/j.hfc.2019.08.006
5. Anker SD, Shahzeb Khan M, Arshad Khan L, et al. The muscle hypothesis of shortness of breath in patients with cachexia. Global Cardiology 2024;2:57. DOI: https://doi.org/10.4081/cardio.2024.57
6. Centers for Disease Control and Prevention (CDC). About multiple cause of death, 1999-2020. Accessed: August 05, 2023. Available from: https://wonder.cdc.gov/mcd-icd10.html.
7. Siddiqi TJ, Khan Minhas AM, Greene SJ, et al. Trends in heart failure-related mortality among older adults in the United States from 1999-2019. JACC Heart Fail 2022;10:851-9. DOI: https://doi.org/10.1016/j.jchf.2022.06.012
8. Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2 2014;1-73.
9. Joinpoint Regression Program, Version 4.9.0.0 - March 2021; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute. Accessed: January 05, 2025. Available from: https://surveillance.cancer.gov/joinpoint/
10. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7-11. DOI: https://doi.org/10.15420/cfr.2016:25:2
11. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. DOI: https://doi.org/10.1093/eurheartj/ehx564
12. Rosano GM, Farkas J. Evolving targets for heart failure: the journey so far. Global Cardiology 2023;1:6. DOI: https://doi.org/10.4081/cardio.2023.6
13. Lena A, Ebner N, Anker MS. Cardiac cachexia. Eur Heart J Suppl 2019;21:L24-7. DOI: https://doi.org/10.1093/eurheartj/suz241
14. Shahzeb Khan M, Butler J, Arshad Khan L, Anker MS. Advanced cancer as a heart failure like syndrome due to cardiac wasting cardiomyopathy: facts and numbers. Global Cardiology 2024;2:58. DOI: https://doi.org/10.4081/cardio.2024.58
15. Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation 2018;138:198-205. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.034271
16. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J 2019;40:3859-68. DOI: https://doi.org/10.1093/eurheartj/ehz835
17. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J 2018;39:1770-80. DOI: https://doi.org/10.1093/eurheartj/ehy005
18. Bekfani T, Pellicori P, Morris DA, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int J Cardiol 2016;222:41-6. DOI: https://doi.org/10.1016/j.ijcard.2016.07.135
19. Collins BC, Arpke RW, Larson AA, et al. Estrogen regulates the satellite cell compartment in females. Cell Rep 2019;28:368-81. DOI: https://doi.org/10.1016/j.celrep.2019.06.025
20. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement From the American Heart Association. Circulation 2017;136:e393-423. DOI: https://doi.org/10.1161/CIR.0000000000000534
21. Mathews L, Ding N, Sang Y, et al. Racial differences in trends and prognosis of guideline-directed medical therapy for heart failure with reduced ejection fraction: the Atherosclerosis Risk in Communities (ARIC) surveillance study. J Racial Ethn Health Disparities 2023;10:118-29. DOI: https://doi.org/10.1007/s40615-021-01202-5
22. Kizer JR, Arnett DK, Bella JN, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 2004;43:1182-8. DOI: https://doi.org/10.1161/01.HYP.0000128738.94190.9f
23. Rosenblatt RA, Andrilla CH, Curtin T, Hart LG. Shortages of medical personnel at community health centers: implications for planned expansion. JAMA 2006;295:1042-9. DOI: https://doi.org/10.1001/jama.295.9.1042
24. Kumar V, Acanfora M, Hennessy CH, Kalache A. Health status of the rural elderly. J Rural Health 2001;17:328-31. DOI: https://doi.org/10.1111/j.1748-0361.2001.tb00282.x
25. López L, Green AR, Tan-McGrory A, et al. Bridging the digital divide in health care: the role of health information technology in addressing racial and ethnic disparities. Jt Comm J Qual Patient Saf 2011;37:437-45. DOI: https://doi.org/10.1016/S1553-7250(11)37055-9
26. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83. DOI: https://doi.org/10.1016/S0140-6736(03)12892-9
27. Maekawa E, Noda T, Maeda D, et al. Prognostic impact of cachexia by multi-assessment in older adults with heart failure: FRAGILE-HF cohort study. J Cachexia Sarcopenia Muscle 2023;14:2143-51. DOI: https://doi.org/10.1002/jcsm.13291
28. Morishita T, Uzui H, Sato Y, Mitsuke Y, Tada H. Associations between cachexia and metalloproteinases, haemodynamics and mortality in heart failure. Eur J Clin Invest 2021;51:e13426. DOI: https://doi.org/10.1111/eci.13426
29. Hadzibegovic S, Porthun J, Lena A, et al. Hand grip strength in patients with advanced cancer: A prospective study. J Cachexia Sarcopenia Muscle 2023;14:1682-94. DOI: https://doi.org/10.1002/jcsm.13248
30. von Haehling S, Ebner N, Dos Santos MR, et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol 2017;14:323-41. DOI: https://doi.org/10.1038/nrcardio.2017.51
31. Clark AL, Coats AJS, Krum H, et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle 2017;8:549-56. d DOI: https://doi.org/10.1002/jcsm.12191
32. Rezk BM, Yoshida T, Semprun-Prieto L, et al. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One 2012;7:e30276. DOI: https://doi.org/10.1371/journal.pone.0030276
33. Talha KM, Pandey A, Fudim M, et al. Frailty and heart failure: State-of-the-art review. J Cachexia Sarcopenia Muscle 2023;14:1959-72. DOI: https://doi.org/10.1002/jcsm.13306
34. Rosano GM. Clinical trial design, endpoints and regulatory considerations in heart failure. Global Cardiology 2024;2:18. DOI: https://doi.org/10.4081/cardio.2024.18
How to Cite
1.
Hameed I, Nashit M, Quettawala Mufaddal Z, Javaid SS, Hanif M. Demographic and regional trends of heart failure and cachexia-related mortality among older adults in the United States, from 1999 to 2020. Global Cardiol [Internet]. 2025 Sep. 19 [cited 2025 Oct. 5];3(3). Available from: https://www.globalcardiology.info/site/article/view/83
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
